MBHB Partner Kevin Noonan Shares Insights on Impacts of Potential NIH Funding Cuts on Biopharma Innovation

In PharmaVoice, MBHB Partner Kevin Noonan discusses the potential impact that proposed funding cuts to the National Institutes of Health may have on biopharma innovation and maintaining the U.S.’s leadership in medical advancements. Read the full article here.